Clinical Trial Update: Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating an IDO pathway inhibitor in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer; the study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemcitabine (Gemcitabine)
• Indoximod (indoximod)

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-04-03